Why Gene Therapy Depends on Counting Stem Cells

by Asymmetrex on March 9, 2016

In a RegMedNet post today (March 9, 2016), Asymmetrex explains that, although much attention is given to molecular genetics advances in the efficiency and integrity of new technologies for gene therapy, failure to count tissue stem cells is likely to limit future treatment success. Sufficient genetic engineering and transplantation of targeted tissue stem cells, like blood hematopoietic stem cells, are crucial for effective gene therapy.  Genetic engineering and gene-editing of rare stem cells face significant competition from abundant committed progenitor cells that can only give short-term treatment.  So, the desired long-term treatment depends heavily on stem cell number that is currently an unknown in gene replacement and gene-editing clinical trials.  In addition to today’s post, Asymmetrex’s founder and director, James L. Sherley, will give a presentation at 4:30 pm to relate how Asymmetrex’s new AlphaSTEM technology for counting adult tissue stem cells can address this important unmet need. The presentation is an invited talk at the Clinical Trials Supply New England 2016 conference taking place in the Revere Hotel in downtown Boston.

Read More
AsymmetrexWhy Gene Therapy Depends on Counting Stem Cells

Asymmetrex Intensifies Value of Counting Adult Stem Cells

by Asymmetrex on March 2, 2016

In Upcoming Webinar and Conferences, Asymmetrex Will Intensify Education on Counting Adult Tissue Stem Cells For Regenerative Medicine and Drug Development

As 2015 drew to a close, stem cell medicine biotechnology start-up company Asymmetrex began an effort to educate the pharmaceutical and regenerative medicine industries on the value of counting adult tissue stem cells. The company is now intensifying this effort with a newly developed free webinar and two scheduled conference presentations to clinical trial developers and the rapidly growing gene-editing therapeutics community.

BOSTON, MA (PRWEB) MARCH 02, 2016

As 2015 drew to a close, stem cell medicine biotechnology start-up company Asymmetrex began an effort to educate the pharmaceutical and regenerative medicine industries on the value of counting adult tissue stem cells. The company is now intensifying this effort with a newly developed free webinar and two scheduled conference presentations to clinical trial developers and the rapidly growing gene-editing therapeutics community.

“Although medicine, science, and technology professionals value innovation highly, they are also trained to be skeptical of it. Myself included. Skepticism runs particularly high when an innovation is not just a better mousetrap, but the first mousetrap. Getting people to try it is even more challenging, if catching mice was previously thought impossible; and might expose a house full of them.”

That’s how James Sherley, Director of Asymmetrex, says he thinks about the challenge his company now faces with gaining acceptance and adoption of its new AlphaSTEM technology for counting adult tissue stem cells. For more than a half century, since its beginnings, the field of stem cell biology has had no method available for counting adult tissue stem cells, though not for lack of trying. However, with the best-described biomarkers found to lack the degree of specificity required for use in counting, stem cell biology and the related translational field of regeneration medicine pretty much gave up on the quest. These fields have been trying to get along without it, in many cases in a state of denial about the negative consequences of trying to do so.

Sherley calls adult tissue stem cell counting “a hidden unmet need” in stem cell research and many related biomedical fields, including drug development, stem cell transplantation medicine, regenerative medicine clinical investigation, gene therapy, and the newly emerging field of gene-editing therapeutics. To provide increased education on these understated or unrecognized deficiencies, starting in January of this year, Asymmetrex has sponsored bi-weekly blogs on the regenerative medicine professionals’ social media network RegMedNet. For example, the blogs highlight fundamental deficiencies in ongoing regenerative medicine trials in which the stem cell number in transplanted treatment preparations is unknown. Without knowing stem cell number, and thereby stem cell dose, how can outcomes be interpreted from one trial to the next?

Asymmetrex is now marketing its AlphaSTEM technology as the long-needed solution to the stem cell counting and stem cell dosing problems. The company is focused on developing interest among executives in pharmaceutical companies, regenerative medicine companies, and gene-editing therapeutics companies. Asymmetrex is also courting contract research organizations, which provide preclinical cell culture assays to pharmaceutical companies, as a strategy to accelerate the introduction of the value of AlphaSTEM technology to their clients for identifying stem cell-toxic drugs earlier during drug development.

Sherley says the key to launching AlphaSTEM technology onward to future sales is industry visibility, education, and increasing prospective client contacts. Over the next several months the company has several scheduled events to boost AlphaSTEM visibility and education. These include a March 9 presentation at Clinical Trial Supply New England 2016, a March 22 free RegMedNet webinar, continued bi-weekly educational blog posts and a to-be-announced online audio interview with Director Sherley on RegMedNet, and a presentation at the 2016 Precision Medicine Symposium –RNAi/MicroRNAs to Stem Cells & Genome Editing on May 4-5.

Whether 2016 will be the year of adult tissue stem cell counting remains to be seen. Sherley says, “If not this year, then the next; but it is inevitable.” He says that the first to adopt the technology will realize a significant advantage over their competitors, whether between academic researchers at the bench, rival pharmaceutical companies, clinical investigators at the bedside, of physicians treating patients with approved stem cell therapies. “It’s too important in human biology not to make a difference.”

About Asymmetrex
Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

Read More
AsymmetrexAsymmetrex Intensifies Value of Counting Adult Stem Cells

Asymmetrex’s Call to Save Money, Patients and Time

by Asymmetrex on February 24, 2016

Today in its company sponsored RegMedNet post, Asymmetrex highlights how its AlphaSTEM technology for counting adult tissue stem cells has potential for high impact in the pharmaceutical industry.  Regenerative medicine also encompasses the application of stem cell fundamentals to identify traditional small molecules and biologics drug candidates to treat disorders of aging, induce or accelerate healing of injuries, as well as treat more familiar diseases and disorders.  By counting tissue stem cells for the first time, Asymmetrex’s AlphaSTEM technology can be used to identify drug candidates that cause intolerable organ and tissue failure because of toxicity against tissue stem cells.  Currently, such failed drugs are not discovered until expensive animal studies or clinical trials with volunteer research subjects and patients.  Such failures for safety are estimated to cost the U.S. pharmaceutical industry $4-5 billion each year.  By screening out stem cell-toxic drug candidates earlier and cheaper, adopting AlphaSTEM technology is projected to save major pharmaceutical companies hundreds for millions of dollars each year, while increasing overall drug safety, and accelerating the identification of effective drugs.

Read More
AsymmetrexAsymmetrex’s Call to Save Money, Patients and Time

Asymmetrex Leading the Dosing Elephant Out of Regenerative Medicine

by Asymmetrex on February 11, 2016

Today Asymmetrex continues its efforts to bring more attention to the long-standing need for tissue stem cell counting in regenerative medicine.  In a post on RegMedNet, the company contrasts the quantitative dosing precision required for pharmaceutical drug trials to the complete vacuum of quantitative dosing for tissue stem cells in regenerative medicine trials.  Asymmetrex invites regenerative medicine companies and physicians’ trials group to evaluate the company’s new AlphaSTEM technology for counting tissue stem cells.  Asymmetrex predicts that adoption of the technology in 2016 would have a major impact on the quality of stem cell medicine clinical trials.

Read More
AsymmetrexAsymmetrex Leading the Dosing Elephant Out of Regenerative Medicine

Asymmetrex Ready to Do a Number for HSC Transplantation Therapies

by Asymmetrex on February 8, 2016

Asymmetrex Ready to Do a Number for Hematopoietic Stem Cell Transplantation Therapies

To prepare the field of regenerative medicine for its AlphaSTEM stem cell counting technology, Asymmetrex makes good on its earlier promise to post on the RegMedNet Industry Developments page an expose on the vexing, but silent, nature of the HSC counting problem in HSCT medicine. Because no earlier technology for counting HSCs has been available, HSCT is the one field of medicine that is unable to determine the dose of its most important medicine, HSCs. Asymmetrex relates the clinical implications of this long-standing shortcoming, in particular how it impacts dire HSCT with umbilical cord blood. To learn more visit RegMedNet.

Read More
AsymmetrexAsymmetrex Ready to Do a Number for HSC Transplantation Therapies

Asymmetrex Supports UK RegMedNet with Sponsorship

by Asymmetrex on February 8, 2016

Asymmetrex Supports UK RegMedNet with Sponsorship for Education on the Importance of Counting Adult Tissue Stem Cells in Regenerative Medicine Practice

Stem cell medicine biotechnology company Asymmetrex is the most recently invited company sponsor to support UK-based RegMedNet, an international network developed to unite the members of the diverse community of regenerative medicine worldwide. In the coming months, the company will focus its sponsorship on informing RegMedNet members of the advantages and value of its new technologies for counting adult tissue stem cells for many applications in regenerative medicine.

In its first post after joining UK RegMedNet as an invited company sponsor, stem cell biomedicine technology company Asymmetrex, now headquartered in Boston, Massachusetts in the U.S, focused on distinguishing regenerative medicine (“RegMed”) companies from other biotechnology enterprises. Generally, RegMed companies do not fit well within common therapeutic and biotechnology classifications as “product” companies or as “platform technology” companies. Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., suggests that instead the new classification, “stem cell fundamentals” companies, better describes the unifying motivation of RegMed companies. RegMed companies “seek to develop one or more fundamental biological properties of stem cells to address important unmet needs in medicine.”

The stem cell fundamental that motivates the business of Asymmetrex is asymmetric self-renewal. This is the biological process by which adult tissue stem cells divide to make simultaneously both unchanged new stem cells and sister cells committed to change to replenish or repair the organs and tissues of the body. Applying its unique expertise in asymmetric self-renewal research, Asymmetrex has developed patented technologies for addressing two important challenges in regenerative medicine, producing adult tissue stem cells and counting them. The goal of the company’s RegMedNet sponsorship is to better inform RegMedNet members of the vital advances that introducing adult tissue stem cell counting into their research and clinical practice would make.

No one would argue that knowing the number of stem cells present in any process involving them would not be important and valuable. Yet, currently, in basic research labs, clinical research labs, medical centers, and hospitals, worldwide, all relevant practices proceed without knowing tissue stem cell number, because this information has been unobtainable. Regenerative medicine battles forth with this same blind spot that stem cell biology has endured for more than half a century.

Asymmetrex has developed innovative technologies to end the non-quantitative state of regenerative medicine. These include new biomarkers with increased specificity for identifying adult tissue stem cells and a new computer simulation technology that is able to count many different types of human adult tissue stem cells. These technologies are an obvious set of new tools for accelerating advances in regenerative medicine. They also have valuable applications in other areas of biomedicine that are impacted by tissue stem cells, like drug development and environmental toxicology.

Asymmetrex plans to work with RegMedNet towards achieving a sea change in how its regenerative medicine community thinks about adult tissue stem cell number. The company’s technologies can demonstrate that in many settings it is now possible to count adult tissue stem cells, for the first time, to great advantage and value. Moving the fields of stem cell biology and regenerative medicine rapidly to a new standard of quantitative practice may take a bit of network chaos first. In the coming months, Asymmetrex will attempt to introduce just such a butterfly effect through RegMedNet to the broader regenerative medicine community.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

Read More
AsymmetrexAsymmetrex Supports UK RegMedNet with Sponsorship

Moving Past The Cliches of Adult Tissue Stem Cells

by Asymmetrex on February 8, 2016

Cliches abound to describe the “unique” properties of adult tissue stem cells.  The lay publications of the National Institutes of Health are full of them.  “Self-renew.” “Differentiate.” “Multipotent.”  The problem with lazy cliches is that they often understate and distort the calming and terrifying beauty of life.  The life of adult stem cells is no different.

5 things you probably didn’t know about adult stem cells

1. It’s hard to distinguish them from other related tissue cells.  So, scientists haven’t be able to count them.

2. Since it hasn’t been possible to count them, doctors treat with them without knowing their dose.

3. If they could be counted, stem cell therapies would improve.

4. Some of them have been shown to hold onto old DNA molecules, called immortal strands.

5. Some scientists think that changes in their DNA (mutations), accumulated over time, play a role in aging.

Read More
AsymmetrexMoving Past The Cliches of Adult Tissue Stem Cells

Moving on to a Future of Counting Adult Tissue Stem Cells

by Asymmetrex on February 5, 2016

With its recently described improved technologies for specifically identifying adult tissue stem cells  or detecting their function by a computer simulation technology, biotech start-up Asymmetrex is anticipating a need for rules to move the field of stem cell biology from a past of common errors and misconceptions to a future of exact quantification.

Asymmetrex’s  5 rules to counting adult tissue stem cells:

1. Consider that there may be no tissue stem cells in the sample.

2. Realize that previously described “stem cell biomarkers” are not specific.

3. Do not call CD34-positive or CD133-positive cells “stem cells,” because >99% are not.

4. Evaluate H2A.Z  asymmetry, a specific tissue stem cell biomarker based on exclusive stem cell functions.

5. Use Asymmetrex’s AlphaSTEM computer simulation technology for counting tissue stem cells.
Read More
AsymmetrexMoving on to a Future of Counting Adult Tissue Stem Cells

Guiding the Inevitable in Stem Cell Medicine

by Asymmetrex on February 5, 2016

As ideas on the potential ability of some adult tissue stem cells to accelerate repair of damaged or injured tissues have grown to be more widely disseminated, so has interest grown in developing stem cell treatments within standard medical practice.  In particular, chronic debilitating ailments like joint pain and low back pain, caused either by injury or degenerative arthritic disease, are currently a major focus of evaluation.  The ability to prepare stem cell-containing treatment samples using standard clinical methods and return them to sites of pain and injury in the same patient has encouraged many physicians to evaluate these unproven therapies for potential benefit for their patients.  Appreciating this development in medical practice, stem cell biotechnology start-up Asymmetrex has developed the following 8recommended guidelines to increase the likelihood that these growing ad hoc evaluations will yield the most benefit to this new field of stemcell medical investigation, as well as the evaluated patients.

Asymmetrex’s 8 guidelines for ad hoc stem cell therapy in the doctor’s office:

1. Employ well-informed consent.

2. Judiciously manage patient expectations.

3. First “do no harm.”

4. Standardize procedures for cell preparation and re-injection

5. Standardize subjective and objective measures of outcome

6. Document

7. Report

8. Stay abreast of FDA guidelines

Read More
AsymmetrexGuiding the Inevitable in Stem Cell Medicine

The Hardest Working Cells in Stem Cell Medicine

by Asymmetrex on February 5, 2016

With the tsunami of research on pluripotent stem cells induced by a 2012 Nobel Prize, in the past several years, adult tissue stem cells experienced a major loss of interest and research effort.  Yet, the greatest progress in stem cell medicine is still due to, in some cases well-known and in other cases not so well known, uses of these natural stem cells.

5 ways adult stem cells are being used in medicine

1. As blood stem cell transplants to support cancer chemotherapy

2. To restore injured corneas

3.  In gene-therapy trials to treat inherited blood disorders (anemias and thalassemias)

4. In clinical trials to improve recovery from strokes and heart attacks

5. In tests for treatment of low back pain
Read More
AsymmetrexThe Hardest Working Cells in Stem Cell Medicine